Vivus Inc., of Mountain View, Calif., said detailed results from the 56-week CONQUER study published in The Lancet showed that obesity candidate Qnexa (phentermine/topiramate) produced an average weight loss of 28 pounds and 22 pounds with the top and mid doses, respectively, compared to four pounds in the placebo group. Data also showed a systolic blood pressure reductions of 4.7 mm Hg (p = 0.0008) and 5.6 mm Hg (p < 0.0001), respectively, vs. 2.4 mm Hg in the placebo group. And Qnexa improved HDL cholesterol by 5.2 percent (p < 0.0001) and 6.8 percent (p < 0.0001), respectively, compared to 1.2 percent for placebo.